Evaluation of IMUGARD III-PL (4P) for Platelet Concentrates
Keywords:
Leukocyte filter, Leukocyte depleted platelet concentratesAbstract
Abstract: This study was carried out to evaluate the ectiveness of IMUGARD III-PL (4P) to remove leukocytes from single donor platelet concentrate (PC) using 24 IMUGARD II-PL (4P) for laboratony use for 24 units of single donor PC. The fitrations were done within 12 hours affer pration and storage at 22'C. The fittions were pormed in closed system. Technicon H3 RTC was used for platelet and white blood cell (WBC) counts for pre and post-flltroducts except for post-fitration, WBC were counled by using Nageotte Brite Line Chamber. The results indicated that prefilitration platelets x 1011/bag ranged from 2.71-5.51 with mean = 3.87 and SD = 0.72, while post-filtration platets x 1011/bag ranged from 2.38-4.92 with mean = 3.39 and SD = 0.67. The percant yield of PC ranged from 77.68 - 93 with mean = 87.58 and SD = 4.40. WBC x 107bag in pre-fittration PC were ranged from 2-320.4 with mean = 73.27 and
SD = 81.52, while post-fitration WBC x 10/bag ranged from 0-0.035 with mean = 0.01 and SD = 0.02. The percent removal of WBC ranged from 99.69-100 with the fitration times ranged from 8 to 11 min/bag. Conclusion: IMUGARD II-PL (4P) is highly effective for leukoftration from single donor PC which is comparable with standard "third ganeration" set. The residual leukocytes were <=0.035x106/bag. Transfusion of PC with WBC to less than 5x106 , non hemoldic transion reaction, CMV transmission and HLA alloimmunization can be reduced.
Downloads
References
Goldman M, Delage G. The role of leukodepletion in the control of transfusion-transmitted disease. Transfus Med Rev. 1995;9:9-19.
Bowden RA, Sichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant Blood 1991;78:246-50.
Brand A. Passebger. Leukocytes cytokines and transfusion reactions. N Engl J Med 1994;331:670-1.
Wenz B. Clinical and laboratory precautions that reduce the adverse reactions. alloimmunization, infectivity and possible immunomodulation associated with homologous transfusion. Transfus Med Rev 1990;4 (Supp 1) : 3-7.
Vengelen-Tyler V, ed. AABB Technical Manual. 12th edition. Maryland USA; 1996:451.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.